Physician profile
Mari E Janko
NPI 1760475628
$3,911.75
in general payments reported to CMS, 2019-2025
23 companies · $653 in 2025
The $653 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $653 · 2022: $917 · 2023: $991 · 2024: $697 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,267 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,266.63 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,434.65 | 2021-2025 | |
| Janssen Biotech, INC. | $440.60 | 2021-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $327.33 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $301.73 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $257.11 | 2021-2023 | Aklief, Oracea, Epsolay |
| Novartis Pharmaceuticals Corporation | $192.78 | 2022-2024 | |
| Pfizer INC. | $132.61 | 2021-2023 | |
| Amgen INC. | $105.10 | 2023-2025 | Otezla, Otezla |
| Ucb, INC. | $94.97 | 2021-2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.46 | 2023-2024 | Spevigo |
| Mayne Pharma Commercial LLC | $79.41 | 2022-2023 | |
| Epi Health, LLC | $62.41 | 2021-2022 | |
| Botanix Sb INC | $54.81 | 2025 | Sofdra |
| Organon LLC | $48.94 | 2025 | Vtama |
| Lilly USA, LLC | $48.74 | 2023-2025 | Taltz, Olumiant, Zepbound |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $45.11 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Sun Pharmaceutical Industries INC. | $43.83 | 2023-2024 | Winlevi |
| Regeneron Healthcare Solutions, INC. | $43.64 | 2021-2025 | Libtayo |
| Almirall LLC | $35.97 | 2022-2025 | Klisyri |
| Journey Medical Corporation | $29.41 | 2022-2023 | |
| Leo Pharma INC. | $15.26 | 2021 | |
| Arcutis Biotherapeutics, INC. | $13.67 | 2023 | |
| Incyte Corporation | $12.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mari Janko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.